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Tumor necrosis factor  (TNF), a proinflammatory cytokine, was shown previously to promote remyelination and oligodendrocyte
precursor proliferation in a murine model for demyelination and remyelination. We used Affymetrix microarrays in this study to identify
(1) changes in gene expression that accompany demyelination versus remyelination and (2) changes in gene expression during the
successful remyelination of wild-type mice versus the unsuccessful attempts in mice lacking TNF. Alterations in inflammatory genes
represented the most prominent changes, with major histocompatibility complex (MHC) genes dramatically enhanced in microglia and
astrocytes during demyelination, remyelination, and as a consequence of TNF stimulation. Studies to examine the roles of these genes
in remyelination were then performed using mice lacking specific genes identified by the microarray. Analysis of MHC-II-null mice
showed delayed remyelination and regeneration of oligodendrocytes, whereas removal of MHC-I had little effect. These data point to the
induction of MHC-II by TNF as an important regulatory event in remyelination and emphasize the active inflammatory response in
regeneration after pathology in the brain.
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Introduction
Inflammation in the CNS is thought to be an exacerbating factor
for many neurodegenerative and demyelinating disorders, most
notably multiple sclerosis (MS). Many products of inflammation
are seen in the plaques of patients with MS and have been pro-
posed to contribute to the destruction of white matter (Brosnan
and Raine, 1996; Sriram and Rodriguez, 1997; Raine et al., 1998);
however, a protective role for neuroinflammation and inflamma-
tory cytokines such as tumor necrosis factor  (TNF) has
emerged recently in models of demyelination and traumatic
brain injury (Eugster et al., 1999; Scherbel et al., 1999; Suvan-
navejh et al., 2000; Juedes and Ruddle, 2001; Arnett et al., 2002).
In addition, the deletion of TNF in mice caused susceptibility to
an immune-mediated demyelination model (Korner et al., 1997;
Liu et al., 1998; Kassiotis et al., 1999). The ability of TNF to
generate multiple and sometimes opposing effects (exacerbatory,
protective, or regenerative) can be attributed in part to the pres-
ence of its two receptors, TNFR1(p55) and TNFR2(p75) (Lock-
sley et al., 2001). In an autoimmune demyelinating model,
TNFR1 has been shown to be involved primarily in the initiation
of demyelination, whereas TNFR2 often appears either unin-
volved or yields a protective effect (Eugster et al., 1999; Suvan-
navejh et al., 2000; Kassiotis and Kollias, 2001). Using a neuro-
toxicant (cuprizone) to induce demyelination and study
remyelination, we demonstrated previously that TNF promotes
remyelination and oligodendrocyte regeneration through
TNFR2 (Arnett et al., 2001).
In agreement with these preclinical studies implicating TNF
in the amelioration of demyelinating disease, the use of anti-TNF
therapy in patients with MS caused disease exacerbation, and its
use in patients with rheumatoid arthritis resulted in new demy-
elinating lesions and new-onset MS (Lenercept Group, 1999;
Mohan et al., 2001; Robinson et al., 2001; Sicotte and Voskuhl,
2001). A better understanding of the observed ability of TNF to
promote remyelination may lead to effective therapeutic inter-
ventions in the treatment of demyelinating diseases. Further-
more, because TNF-null mice are defective in their ability to
remyelinate, they provide a unique model for identifying factors
important to this process.
To analyze global changes that occur during demyelination,
remyelination, and TNF-directed remyelination in the cupri-
zone model, we now use Affymetrix cDNA microarrays to iden-
tify (1) genes that accompany demyelination versus remyelina-
tion and (2) gene differences in wild-type and TNF-null to
compare successful versus unsuccessful remyelination. The
latter are especially interesting because they should include
differences that are critical to the regeneration of myelin and
oligodendrocytes.
Our findings show alterations in genes involved in such di-
verse functions such as cell division, signaling, transcription, and
development, although the largest category of genes upregulated
during both demyelination and remyelination relates to inflam-
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mation and the immune response. A number of candidate genes
that may be involved in the inflammation-driven regeneration of
oligodendrocytes are downstream of TNF during successful re-
myelination. We chose major histocompatibility complexes
(MHCs) I and II for further analysis because the expression pat-
terns of both were enhanced significantly during remyelination
and altered by TNF. Furthermore, both MHC-I and -II are
known to be present in demyelinating and remyelinating plaques
of patients with multiple sclerosis, (Olsson, 1992).
Materials and Methods
Mice. C57BL/6J control mice were purchased from Jackson Laboratories
(Bar Harbor, ME). MHC-I-deficient B2m  /  mice (B2mtm1Unc) were
purchased from Jackson Laboratories, previously backcrossed 11 times
to a C57BL6/J background (Koller et al., 1990). MHC-II  /  mice (lack-
ing A) were bred in-house and backcrossed eight times to a C57BL6/J
background (Grusby et al., 1991). TNF  /  mice were backcrossed
nine times to a C57BL6/J background at Memorial Sloan-Kettering Can-
cer Center and maintained in our animal facility at University of North
Carolina for testing (Marino et al., 1997). All animal procedures were
conducted in pathogen-free conditions with complete compliance to the
National Institutes of Health Guide for the Care and Use of Laboratory
Animals and were approved by the Institutional Animal Care and Use
Committee of the University of North Carolina at Chapel Hill.
Induction of demyelination and remyelination. To induce demyelina-
tion, male mice, 8 –10 weeks old, were fed a diet of milled Purina mouse
chow containing 0.2% cuprizone (Sigma, St. Louis, MO) for up to 6
weeks. Remyelination was initiated by returning the mice to a normal
diet after 6 weeks of cuprizone (Morell et al., 1998; Matsushima and
Morell, 2001).
RNA isolation. Total RNA was isolated from a dissected region of the
corpus callosum of wild-type and TNF  /  mice at several points in
treatment. RNA isolation was performed using the Qiagen RNeasy kit
under RNase-free conditions (Qiagen, Valencia, CA). Purity was deter-
mined by A260/A280, by denaturing agarose gel electrophoresis, and by
negative results after PCR for genomic contamination.
Microarray analysis. To profile gene expression differences, we used
Affymetrix GeneChip arrays in which sets of oligonucleotides are immo-
bilized on a chip and then hybridized with labeled RNA. These experi-
ments used the mouse genome U74Av2 chips containing gene probes for
6000 genes in the Mouse Unigene database as well as 6000 expressed
sequence tags clusters. cDNA synthesis was performed with the Super-
script II system (Invitrogen/BRL, Grand Island, NY) and in vitro tran-
scription labeling with biotinylated UTP and CTP was performed ac-
cording to the manufacturer’s recommendations (Enzo Diagnostics,
Farmingdale, NY). Amplified cRNA was purified on an affinity column
(Qiagen), and the quality of the amplification was verified by denaturing
agarose gel electrophoresis. cRNAs were fragmented and then hybridized
to prewetted array chips. Chips were washed according to Affymetrix
washing protocols and subsequently stained using a fluorochrome–avi-
din conjugate. The probe arrays were scanned with the GeneChip system
confocal scanner (Affymetrix, Santa Clara, CA). For an individual gene,
hybridization of cRNA to a set of perfectly matched oligonucleotide se-
quences versus hybridization to a set of single mismatch oligonucleotide
sequences yields a signal that is reflective of the level of expression of that
gene. Data generated were analyzed using Genespring software. To lend
greater fidelity to the data, this experiment was repeated, each with an
RNA pool of three mice per strain and over the three chosen time points.
Quantitative real-time RT-PCR. TaqMan 5 nuclease real-time PCR
assays were performed using an ABI Prism 7900 sequence-detection sys-
tem (PE Applied Biosystems, Foster City, CA) in a 15 l reaction with
universal master mix (Life Technologies/ BRL), 200 nM target primers,
and 100 nM probe. Primers were designed to span intron– exon junctions
to differentiate between cDNA and genomic DNA. The primers and
probe used to detect mouse MHC-II (IA of b haplotype) were as follows:
5 primer, GAGCATCCCAGCCTGAAGA; 3 primer, CGATGCCGCT-
CAACATCTT; probe, Fam-ACTCAGACTGTGCCCTC CACTCCA-
Tamra. The primers and probe for mouse MHC-I (H2D of b haplotype)
were 5 primer, GCTCCTCACTTCCACACTGAGA; 3 primer, GGAA-
GAGCAGTCAGCGCTAGA; probe, Fam-AATAATTTGAATGTGGGT-
GGCTGGAGAGATG-Tamra. The primers and probe for mouse 18 S
ribosomal RNA were 5 primer, GCTGCTGGCACCAGACTT; 3 primer,
CGGCTACCACATCCAAGG; probe, Tet-CAAATTACCCACTCCCGAC-
CCG-Tamra. Thermal cycle parameters were optimized to 2 min at 50°C,
2 min at 95°C, and 40 cycles comprising denaturation at 95°C for 15 sec
and annealing– extension at 56°C for 1.5 min. Reactions for 18 S were
performed during each experiment and used to normalize for amounts
of cDNA. Presented results are representative of three separate trials,
each performed in duplicate.
Histology and electron microscopy. Animals were prepared for frozen,
paraffin, and electron microscopy (EM) sections as described previously
(Arnett et al., 2001). Paraffin sections were stained with luxol-fast blue
(LFB)/periodic acid Schiff for myelin, glutathione S-transferase (GST-)
for mature oligdodendrocytes (Biotrin, Newton, MA; 1:500), RCA-1 for
microglia (Vector, Burlingame, CA; 1:500), and GFAP for astrocytes
(Dako, Carpinteria, CA; 1:100). We quantified immunopositive cells by
counting positive cells within the median of the corpus callosum, con-
fined to a 0.033 mm 2 area. Only those stained cells with an observable
nucleus by DAPI stain or light microscopy were counted. Cell counts are
presented as averages from at least six mice per time point. Frozen sec-
tions were stained for MHC-I (TIB126; American Type Culture Collec-
tion, Manassas, VA; 1:100) and MHC-II (PharMingen, San Diego, CA;
1:10) as well as the above antibodies for colocalization. EM ultrathin
sections were stained with uranyl acetate and lead citrate as described
(Coetzee et al., 1996).
Statistics. Data are expressed as mean  SD. Comparisons were statis-
tically evaluated using ANOVA followed by a Bonferonni post hoc anal-
ysis. Results were considered significant if p  0.05.
Results
Remyelination in mice lacking TNF
The use of cuprizone, a copper chelating agent delivered through
the diet, causes demyelination that is predictable in pathology
and time course. Removal of cuprizone for 1 week causes detect-
able remyelination that progresses with time. Using this model,
we confirmed previous findings that the degree of myelination in
the corpus callosum of TNF /  and wild-type mice before
cuprizone treatment is indistinguishable, as is their degree of
demyelination and oligodendrocyte loss after an extended 5
weeks of cuprizone treatment (Arnett et al., 2001). Wild-type
mice, however, underwent rapid remyelination after removal of
cuprizone, whereas TNF /  mice failed to remyelinate effec-
tively (Fig. 1) (Arnett et al., 2001).
Figure 1. TNF in remyelination. Electron microscopy was performed on cross-sections
of the corpus callosum in wild-type and TNF /  mice. Analysis is shown in untreated
mice, after complete demyelination with the cuprizone, and after 2 weeks of remyelina-
tion. Scale bar, 2 m.
Arnett et al. • cDNA Microarray Analysis of Remyelination J. Neurosci., October 29, 2003 • 23(30):9824 –9832 • 9825
Table 1. Transcripts altered in demyelinated and remyelinating lesions
Affymetrix gene chip analysis was performed on corpus callosum RNA from wild-type mice at time points representing normal levels of myelin, complete demyelination, and active remyelination. Gene expression data are presented for the
demyelinated and remyelinating time points as fold changes above or below (shown in red as a negative value) the expression data for the untreated mice. Only those genes with a raw value of 1000 in at least one condition, an
approximately threefold change in expression, and an SE of 0.4 of the normalized values in duplicate experiments were included for analysis. AP denotes that the expression of that gene was absent in untreated samples and present in
treated samples; PA denotes that a gene went from present in untreated samples to absent in treated samples. Genes are grossly categorized according to their function, with genes of unknown function or functions other than those listed
available as supplemental data (available at www.jneurosci.org). The immune and stress response genes are further divided according to their patterns of expression: Type A genes are upregulated after demyelination and recede during
remyelination; type B genes are upregulated and stay upregulated during remyelination; type C genes are downregulated during demyelination.
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Transcripts altered in demyelinated and
remyelinating lesions
To profile gene expression differences, we used Affymetrix Gene-
Chip arrays in which sets of oligonucleotides were immobilized
on a chip and then hybridized with labeled cDNA. Three time
points were chosen: untreated, 5 weeks of cuprizone treatment
(representing the complete demyelination of the corpus callo-
sum), and 6 weeks of treatment followed by 1 week of recovery (7
weeks; representing active remyelination). Data were analyzed in
duplicate by comparison-based analysis. Only those genes with a
raw value of 1000 in at least one condition and a greater than
threefold change in expression over control were included for
analysis. The overall correlation coefficient between replicate
samples ranged from 0.5 to 0.8, and for an individual gene to be
included for analysis, the SE between replicates was required to be
0.4 of the normalized values. These relatively strict standards
are likely to generate false-negative signals but less likely to pro-
duce false-positive signals.
Table 2. Genes altered in mice lacking TNF after demyelination and during remyelination
Affymetrix gene expression data from corpus callosum of wild-type mice were compared to that of TNF/ mice with similar treatments. The data are shown for TNF/ mice as fold changes above or below (shown in red as a negative
value) their counterpart wild-type mice. Only those genes with a raw value of 1000 in at least one condition, an approximately threefold change in expression, and SE of 0.4 of the normalized values in duplicate experiments were
included for analysis. AP denotes that the expression of that gene was absent in untreated samples and present in treated samples; PA denotes that a gene went from present in untreated samples to absent in treated samples. Genes are
grossly categorized according to their function, with genes of unknown function or functions other than those listed available as supplemental data (available at www.jneurosci.org).
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As expected, demyelination and oligodendrocyte apoptosis
lead to the rapid downregulation of oligodendrocyte- and
myelin-related genes, as shown through the gene array analysis
(Table 1). These include myelin– oligodendrocyte glycoprotein
(MOG), myelin-associated glycoprotein (MAG), myelin proteo-
lipid protein (PLP), and myelin- and lymphocyte-specific pro-
tein (MAL). Genes involved in diverse functions such as cell cycle,
development, and signal transduction constitute large groups of
altered genes; however, the largest category of genes altered dur-
ing both demyelination and remyelination consists of inflamma-
tory and stress-response genes (Table 1). The data underscore the
massive inflammatory response mounted during demyelination
and remyelination. Some of these include GFAP, a marker for
astrogliosis, and markers for microglia–macrophage, which have
been documented to be upregulated during cuprizone treatment
(Hiremath et al., 1998). The two largest components of immune-
related genes that were induced after demyelination are MHC-
and complement-related genes. Cytokines, cytokine receptors,
and other inflammatory mediators were enhanced. Multiple en-
zymes involved in lysosomes including cathepsins C, H, and Z
and lysoszymes M and P were also upregulated. These proteolytic
enzymes may be related to the increased microglia–macrophage
phagocytosis of the disrupted myelin or to the processing of an-
tigens by MHC-I and -II. Lysozymes are often considered mark-
ers of activated cells of monocytic origin and have been shown
previously to correlate with the recruitment of microglia–mac-
rophages after demyelination (Morell et al., 1998; Jurevics et al.,
2002).
Two primary patterns of gene expression are observed among
the immune genes shown in Table 1. In the group labeled Type A,
the genes were upregulated during demyelination but then re-
versed to basal levels. In the group labeled Type B, the genes were
upregulated during both demyelination and remyelination. Re-
markably, most of the immune response genes belong to the
latter. This suggests that the immune transcripts upregulated
during remyelination do not represent a subset of the immune
response but rather a more generalized effect. It also implicates
inflammatory genes as important components of remyelination.
Transcripts altered in mice lacking TNF
To identify genes that are involved in remyelination, it is impor-
tant to compare gene expression profiles of mice that have un-
dergone successful remyelination with those that have exhibited
unsuccessful or delayed remyelination. The results with
TNF /  mice (Fig. 1) indicate that a comparison of these mice
with wild-type mice during the remyelination phase should re-
veal genes that are putatively important for remyelination. Af-
fymetrix analyses of cDNA from the corpus callosum of these two
sets of mice were performed at the following time points: before
cuprizone treatment, when demyelination was completed in both
strains (5 weeks of cuprizone treatment), and when remyelina-
tion was substantial in the wild-type mice, but delayed in the
TNF /  mice (at 7 weeks, when cuprizone was removed for the
last week).
In agreement with the histologic and pathologic analysis,
TNF /  and wild-type mice showed few differences in gene
expression before cuprizone treatment (data not shown). In con-
trast, significant differences were found between TNF /  and
wild-type mice after demyelination as well as during remyelina-
tion (Table 2). Because TNF /  mice showed defective remy-
elination at the week 7 time point, special emphasis was placed on
these gene differences. The primary categories of genes that were
expressed more highly in wild-type mice than TNF /  mice
during the remyelinating phase include immune response, sig-
naling, and developmental and transcriptional regulation (Table
2). Notably several genes in the MHC family were reduced in
mice lacking TNF.
Figure 2. Expression of MHC-I and -II. A, B, Quantitative analysis of MHC-I and -II transcripts
using quantitative real-time RT-PCR on total RNA isolated from the corpus callosum during
demyelination and remyelination in wild-type mice. Each bar represents the averaged fold
induction over untreated wild-type mice of at least three mice per genotype per time point
(SD). The scale is interrupted to accommodate the large value obtained for MHC-II with
wild-type mice after 4 weeks of cuprizone treatment. C, D, Quantitative analysis of MHC-I and -II
transcripts in wild-type mice compared with that in mice lacking TNF. *p  0.05. E, Antibod-
ies were used to localize expression of MHC-I and -II (green) during demyelination of wild-type
mice and colocalized to microglia (RCA-1, red) and astrocytes (GFAP, blue). Yellow indicates
colocalization of the red and green fluorochromes. Scale bar, 12.5 m.
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Expression of MHC-I and -II during demyelination
and remyelination
The considerable number of MHC-related genes that were en-
hanced during demyelination and remyelination in wild-type
mice and their alteration by the absence of TNF implicate a role
for these genes in the control of remyelination. We verified ex-
pression of MHC-I and -II in this disease model through quan-
titative real-time RT-PCR at time points
additional to those included in the Af-
fymetrix analysis. This analysis shows sim-
ilar patterns of increases in the transcrip-
tion of MHC-I and -II during cuprizone-
induced inflammation, with the peak of
expression occurring at 4 weeks of cupri-
zone treatment (Fig. 2A,B). This time
pointcorrelateswith thepeakofmicroglia–
macrophage infiltration into the corpus
callosum (Hiremath et al., 1998). Elevated
MHC-I and -II expression was maintained
during remyelination, although the level
decreased at the 8-week endpoint. Levels
of MHC-I and -II were decreased after
demyelination and remyelination in the
absence of TNF ( p  0.05) (Fig. 2C,D),
although the degree of microglia–macro-
phage recruitment was similar in the wild-
type and TNF /  mice in this model
(Arnett et al., 2001). Thus, transcription of
both MHC-I and -II genes is induced by
TNF, but TNF is not required for MHC
gene expression because expression is still
observed in TNF /  mice. Detectable
MHC-I (Fig. 2E, green) predominantly lo-
calizes to both microglia (red) and astro-
cytes (blue) in the demyelinating lesion.
MHC-II is expressed primarily on micro-
glia but also occasionally on astrocytes
(Fig. 2E).
Roles of MHC-I and -II in remyelination
To perform functional genomic analysis,
we characterized the roles of MHC-I and
-II in remyelination using mice lacking ex-
pression of MHC-I or -II. The mice used to
study the former lack B2m, which is essen-
tial for the expression of properly folded
MHC-I protein (Koller et al., 1990). The
mice used to study the latter lacked A
chain, which eliminates I-A expression
(Grusby et al., 1991). Because of a natural
defect in the E promoter of MHC II, this
strain lacks all MHC-II expression. Un-
treated wild-type and MHC-I or -II null
mice exhibited similar degrees of myelina-
tion before treatment (Fig. 3A, B, untreat-
ed). The degree of demyelination was de-
termined by the extent of LFB staining and
was read in a double-blind manner by
three investigators. All three strains were
also completely demyelinated after the ex-
tended 5 weeks of cuprizone treatment
(Fig. 3A,B, 5 weeks). When the toxin was
removed, wild-type mice and MHC-I / 
mice exhibited rapid remyelination within 1 week, which pro-
gressed steadily by 2 weeks (Fig. 3A, 7 and 8 weeks). In dramatic
contrast, MHC-II /  mice demonstrated a significant delay in
remyelination ( p  0.05) (Fig. 3B, 7 and 8 weeks).
LFB analysis is a qualitatitve measurement of myelination.
Ultrastructural analysis and quantitation by electron micro-
scopic inspection represent much more accurate approaches to
Figure 3. MHC-I and -II in remyelination. A, B, Wild-type mice, MHC-I-null mice, and MHC-II-null mice were analyzed at various
time points during demyelination and remyelination. Sections containing the corpus callosum at the level of the fornix were
stained for LFB/PAS, and the corpus callosum was scored by three investigators on a scale of 0 (completely myelinated) to 3
(completely demyelinated), with the presence of blue fibers indicative of intact myelin. *p  0.05. C, Remyelination was exam-
ined further with electron microscopy. Pictures represent a cross-section of the corpus callosum at the level of the fornix in
untreated mice, mice completely demyelinated with cuprizone, and mice allowed to remyelinate for 1 week. Scale bar, 2 m. D,
g-ratios and percentage unmyelinated fibers were calculated from a minimum of 200 fibers per mouse per time point. *p0.001.
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determine the extent of myelination in
MHC-II / versus wild-type mice (Fig.
3C). A measurement of myelination, the
g-ratio, was calculated as the ratio of the di-
ameter of the axon to the diameter of the
axon and surrounding myelin. Three mice
from each group at each time point were
tested, and a minimum of 200 fibers per
mouse per strain per time point were mea-
sured. This provides an assessment of the
percentage of unmyelinated axons through-
out the treatment protocol in wild-type and
MHC-II-null mice (Fig. 3D). A typical
g-ratio for a normally myelinated axon is be-
tween 0.6 and 0.8, where a g-ratio of 1.0 is
completely demyelinated. After 5 weeks of
treatment, 88–89% of axons in the corpus
callosum of wild-type and MHC-II /
mice were completely demyelinated. Within
1 week of remyelination, 32% of wild-type
axons remained demyelinated compared
with 78% in MHC-II / mice.
During the demyelination process, ma-
ture oligodendrocytes in the corpus callo-
sum undergo apoptosis (Mason et al.,
2000). Remyelination is initiated with the
reappearance of new myelinating oligo-
dendrocytes in the lesion. The oligoden-
drocytes in wild-type and MHC-II / 
mice were depleted from the corpus callo-
sum to similar degrees after 5 weeks of cu-
prizone treatment; however, after 1 week
of recovery, wild-type mice had twofold
more oligodendrocytes in the corpus cal-
losum than MHC-II /  mice ( p  0.05)
(Fig. 4A,B). In contrast, the results with
MHC-I /  mice are indistinguishable
from wild-type mice. This finding suggests
that MHC-II is important in the regenera-
tion of new oligodendrocytes and explains
the delay in remyelination observed in
mice lacking MHC-II.
Discussion
In an effort to identify important factors in myelination, we have
identified patterns of gene expression observed during
cuprizone-induced demyelination and remyelination in wild-
type mice. These were compared with TNF /  mice, which
showed retarded remyelination. Two of the most impressive
findings are the predominance of immune and stress response
genes during both demyelination and remyelination, and the sig-
nificant effects of TNF on inflammatory gene expression. In
particular, MHC-II is upregulated during both demyelination
and remyelination, is controlled by TNF, and is important for
the reappearance of new, myelinating oligodendrocytes required
for successful remyelination. Interestingly, the genes for TNF
and MHC-II are proximal to each other, and they represent the
only consistent linkages to MS susceptibility in humans (Fuka-
zawa et al., 2000; Kantarci et al., 2002). Further study of MHC-II
and other genes identified in this screen could establish them as
important and novel therapeutic targets in demyelinating
diseases.
Cuprizone is an ideal model for studying demyelination, re-
myelination, and the role of neuroinflammation. The induction
of demyelination and remyelination is easy to administer, and the
outcome is predictable in pathology and disease course. Admin-
istration of cuprizone to mice results in an impressive inflamma-
tory reaction reflected by tremendous microglial accumulation
and astrogliosis (Hiremath et al., 1998; Arnett et al., 2001; Mc-
Mahon et al., 2001). In retrospect, it is not surprising that most of
the genes upregulated after demyelination and during remyelina-
tion are involved in the inflammatory response. Remarkably,
many of these immune response genes are related to the MHC
family.
MHC-I and -II are increased under a wide range of pathologic
conditions and play multiple roles during inflammation in the
CNS (Neumann, 2001). In the brain, these factors have been most
studied in the presentation of antigens in murine experimental
autoimmune encephalitis in which demyelination follows the
generation of myelin-reactive T lymphocytes. The presence of
MHC-II has also been shown to be protective for regeneration
and axon integrity in a mouse model of viral encephalitis (Njenga
et al., 1999). Low levels of MHC-I are present on most cells and
Figure 4. MHC-II and the regeneration of oligodendrocytes. A, Oligodendrocytes were identified during demyelination
and remyelination in wild-type mice and mice lacking MHC-I or -II using an antibody to GST- (red). B, Quantification of
oligodendrocytes in the corpus callosum. Each bar represents an average of the results of at least six mice per genotype per
time point. *p  0.05.
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function by presenting endogenous foreign peptides to CD8
cells. Alternatively, MHC-II is present on professional antigen-
presenting cells, including macrophages and dendritic cells, and
presents exogenous antigenic peptides to CD4 cells. Both mi-
croglia and astrocytes express MHC-II in vitro, but microglia
appear to represent the predominant MHC-II-positive cells in
vivo, similar to our observations in this study (Dong and Ben-
veniste, 2001).
Although antigen presentation is a primary function of
MHC-I and -II, a T lymphocyte infiltrate is not easily found in the
cuprizone model, where the blood– brain barrier remains intact
(Matsushima and Morell, 2001). Furthermore, the remyelination
phase is independent of T cells as shown by the use of RAG / 
mice, which lack lymphocytes (Arnett et al., 2001). MHC-II has
been previously hypothesized to have signaling functions in mi-
croglia and macrophages independent of T lymphocytes through
its cytoplasmic domain. MHC-II has been demonstrated to con-
tribute to the activation of microglia–macrophage in the brain in
a model of Krabbes disease, in which lymphocytes are also not
known to play a role (Matsushima et al., 1994). Future experi-
ments will be directed at addressing the signaling potential of
MHC-II in this model.
The use of gene array analysis has provided extraordinary in-
sights regarding gene alterations during different permutations;
however, the significance of functional genomics is underscored
by the failure to find a role for MHC-I in the remyelination phase
despite significant changes in this and related genes during de-
myelination, remyelination, and after TNF deletion. The most
straightforward possibility is that TNF, a well known inducer of
MHC-I (Panek et al., 1994; Neumann et al., 1997), obligatorily
induces MHC-I, but this has no biologic consequences on the
myelination process. Another possibility is that the enhanced lev-
els of MHC-I have functions that are not revealed by our analysis.
We have used mice lacking B2m, which might not be the same as
a deletion of the gene for MHC-I, because expression of “empty”
MHC-I can be forced on cells without B2m (Allen et al., 1986; Bix
and Raulet, 1992). We are aware that previous studies of trans-
genic mice with MHC-I expression in oligodendrocytes have ob-
served alterations in myelination (Turnley et al., 1991). In those
studies, however, the expression of MHC-I is forced and on oli-
godendrocytes, which do not normally express MHC.
Although it is clear that TNF and MHC-II are involved in the
regeneration of oligodendrocytes and remyelination, the mecha-
nism for the precise involvement of the immune system in remy-
elination is unclear. One possibility is that the expression of these
inflammatory molecules causes the upregulation, either directly
or indirectly, of factors that contribute to the proliferation and
maturation of new progenitors. This study supports that hypoth-
esis by showing an upregulation of multiple transcription factors
and other proteins with known functions in the development of
the CNS after the immune response to demyelination.
In summary, this study supports the possibility that inflam-
mation has its use in the repair of demyelination, although not all
immune-related molecules that are enhanced during remyelina-
tion appear to have a direct functional impact on this process.
Sorting out the inflammatory processes that are beneficial versus
those that may be harmful is crucial to the design of improved
therapies for demyelinating or dysmyelinating disorders.
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